NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International)
NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International)
Pricing its initial public offering at CHF18 per share - the bottom of its expected range of CHF18 to CHF22 - Arpida AG realized gross proceeds of CHF97.2 million (US$80.9 million) from its debut on the Swiss Stock Exchange May 4. (BioWorld International)
Pricing its initial public offering at CHF18 per share - the bottom of its expected range of CHF18 to CHF22 - Arpida AG realized gross proceeds of CHF97.2 million (US$80.9 million) from its debut on the Swiss Stock Exchange May 4. (BioWorld International)
